The latest price target for BioRestorative Therapies (NASDAQ: BRTX) was reported by Roth Capital on December 7, 2022. The analyst firm set a price target for $15.00 expecting BRTX to rise to within 12 months (a possible 361.57% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for BioRestorative Therapies (NASDAQ: BRTX) was provided by Roth Capital, and BioRestorative Therapies initiated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioRestorative Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioRestorative Therapies was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.

While ratings are subjective and will change, the latest BioRestorative Therapies (BRTX) rating was a initiated with a price target of $0.00 to $15.00. The current price BioRestorative Therapies (BRTX) is trading at is $3.25, which is within the analyst's predicted range.